Holen Sie sich die Stockscreener-App
14.60
2.10%
0.30
Handel nachbörslich:
14.64
0.04
+0.27%
Schlusskurs vom Vortag:
$14.30
Offen:
$14.38
24-Stunden-Volumen:
545.55K
Relative Volume:
0.44
Marktkapitalisierung:
$801.06M
Einnahmen:
$15.84M
Nettoeinkommen (Verlust:
$-308.48M
KGV:
-2.2531
EPS:
-6.48
Netto-Cashflow:
$-153.08M
1W Leistung:
+8.23%
1M Leistung:
+1.39%
6M Leistung:
+10.19%
1J Leistung:
+107.39%
1-Tages-Spanne:
$14.35
$14.88
1-Wochen-Bereich:
$12.89
$14.88
52-Wochen-Spanne:
$4.45
$19.18
Uniqure N V Stock (QURE) Company Profile
Firmenname
Uniqure N V
Sektor
Branche
Telefon
1-339-970-7000
Adresse
PAASHEUVELWEG 25A, AMSTERDAM
Vergleichen Sie QURE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
QURE
Uniqure N V
|
14.60 | 774.72M | 15.84M | -308.48M | -153.08M | -6.48 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Uniqure N V Stock (QURE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-01 | Fortgesetzt | Chardan Capital Markets | Buy |
| 2024-12-10 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2024-10-10 | Fortgesetzt | Raymond James | Outperform |
| 2024-02-29 | Herabstufung | Goldman | Buy → Neutral |
| 2023-12-19 | Herabstufung | Mizuho | Buy → Neutral |
| 2022-03-17 | Hochstufung | UBS | Neutral → Buy |
| 2021-06-15 | Eingeleitet | BTIG Research | Buy |
| 2021-05-21 | Eingeleitet | UBS | Neutral |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-04-01 | Hochstufung | Mizuho | Neutral → Buy |
| 2021-01-07 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-11-24 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-11-11 | Eingeleitet | Berenberg | Buy |
| 2020-11-09 | Eingeleitet | Jefferies | Buy |
| 2020-11-04 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-10-23 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2020-08-25 | Eingeleitet | Raymond James | Strong Buy |
| 2020-07-31 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2020-06-25 | Herabstufung | Mizuho | Buy → Neutral |
| 2020-06-25 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-06-25 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2019-12-03 | Eingeleitet | Cowen | Outperform |
| 2019-12-03 | Eingeleitet | Goldman | Buy |
| 2019-11-05 | Eingeleitet | Credit Suisse | Outperform |
| 2019-10-11 | Eingeleitet | Stifel | Buy |
| 2019-09-25 | Eingeleitet | Bernstein | Outperform |
| 2019-09-12 | Eingeleitet | Mizuho | Buy |
| 2019-07-30 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-07-08 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2019-04-12 | Eingeleitet | Piper Jaffray | Overweight |
| 2019-03-29 | Eingeleitet | Robert W. Baird | Outperform |
Alle ansehen
Uniqure N V Aktie (QURE) Neueste Nachrichten
Institutional Ownership Dominates uniQure N.V., Hedge Funds Hold 19% - AInvest
uniQure N.V. (NASDAQ:QURE) is favoured by institutional owners who hold 55% of the company - uk.finance.yahoo.com
Uniqure N.V. shares rise 1.04% after-hours following PTC Therapeutics' positive Q2 earnings report. - AInvest
Aberdeen Group Expands Stake in uniQure with Strategic Acquisition - AInvest
Aberdeen Group plc Expands Stake in uniQure NV with Strategic Ac - GuruFocus
Is uniQure N.V. a good long term investmentGet exclusive access to premium stock research - Jammu Links News
What is uniQure N.V. company’s growth strategyStrongest growth potential - Jammu Links News
Should I hold or sell uniQure N.V. stock in 2025Unlock daily market insights for better trades - Jammu Links News
What makes uniQure N.V. stock price move sharplyBuild a strong portfolio for long-term success - Jammu Links News
What drives uniQure N.V. stock priceUnprecedented market success - Jammu Links News
Is uniQure N.V. a growth stock or a value stockMaximize returns with disciplined investment techniques - Jammu Links News
What is the risk reward ratio of investing in uniQure N.V. stockOutstanding growth strategies - Jammu Links News
What are the latest earnings results for uniQure N.V.Discover undervalued stocks before they soar - Jammu Links News
How does uniQure N.V. compare to its industry peersMaximize your gains with expert trading tips - Jammu Links News
Is uniQure N.V. stock overvalued or undervaluedDiscover high-impact stocks for your portfolio - Jammu Links News
What analysts say about uniQure N.V. stockDiscover breakthrough stocks before the crowd - Jammu Links News
How strong is uniQure N.V. company’s balance sheetBuild wealth faster with professional insights - Jammu Links News
What are the technical indicators suggesting about uniQure N.V.High-octane gains - Jammu Links News
Why is uniQure N.V. stock attracting strong analyst attentionEntry Signal Signals To Watch Now - Jammu Links News
UniQure N.V. (NASDAQ:QURE) Just Released Its Second-Quarter Earnings: Here's What Analysts Think - 富途牛牛
A Quick Look at Today's Ratings for UniQure NV(QURE.US), With a Forecast Between $35 to $35 - 富途牛牛
uniQure Reports Q2 2025 Progress and Financials - TipRanks
uniQure’s AMT-130 Gene Therapy for Huntington’s Disease on Track for Q1 2026 BLA Submission After FDA Alignment - Insider Monkey
Huntington’s Disease Market to Expand Significantly by 2034, States DelveInsight Report | Prilenia Therapeutics, Neurocrine Biosciences, Som Biotech, Annexon Biosciences, Vaccinex, Sage Therapeutics - Barchart.com
Wall Street Analysts Think uniQure (QURE) Could Surge 142.67%: Read This Before Placing a Bet - Zacks Investment Research
uniQure N.V. (NASDAQ:QURE) Q2 2025 Earnings Call Transcript - Insider Monkey
RBC Capital Maintains UniQure NV(QURE.US) With Buy Rating, Maintains Target Price $24 - 富途牛牛
uniQure N.V. Earnings Call: Progress Amid Challenges - TipRanks
Chardan Capital Analyst Downgrades uniQure Price Target to $35.00, Maintains Buy Rating - AInvest
What Caused uniQure’s (QURE.O) Sudden Intraday Surge? - AInvest
What's Going On With Sarepta, Capricor And Other Gene Therapy Stocks On Wednesday? - Benzinga
UniQure outlines planned BLA submission for AMT-130 in Q1 2026 amid regulatory alignment and pipeline momentum - MSN
UniQure shares rise 9.65% premarket after FDA alignment on AMT-130 statistical analysis plan and CMC requirements. - AInvest
UniQure: Q2 Earnings Snapshot - Huron Daily Tribune
UniQure shares rise 12.35% premarket after FDA alignment on AMT-130 and positive clinical data. - AInvest
uniQure NV (QURE) Q2 2025 Earnings Call Highlights: Navigating R - GuruFocus
Chardan Capital maintains Buy rating for uniQure with $35 PT. - AInvest
Mizuho Securities Maintains UniQure NV(QURE.US) With Hold Rating - 富途牛牛
uniQure shares tumble as Q2 revenue misses expectations By Investing.com - Investing.com Canada
uniQure shares tumble as Q2 revenue misses expectations - Investing.com
uniQure Announces $200 Million Sales Agreement - TipRanks
Finanzdaten der Uniqure N V-Aktie (QURE)
Umsatz
Nettogewinn
Free Cashflow
ENV
Uniqure N V-Aktie (QURE) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Springhorn Jeremy P. | Director |
Jun 20 '25 |
Sale |
14.45 |
2,112 |
30,518 |
37,694 |
| POST LEONARD E | Director |
Jun 20 '25 |
Sale |
14.45 |
2,112 |
30,518 |
29,937 |
| Kaye Jack | Director |
Jun 20 '25 |
Sale |
14.45 |
2,112 |
30,518 |
20,439 |
| Jacques Rachelle Suzanne | Director |
Jun 20 '25 |
Sale |
14.45 |
2,112 |
30,518 |
28,346 |
| Gut Robert | Director |
Jun 20 '25 |
Sale |
14.45 |
3,336 |
48,205 |
56,879 |
| Balachandran Madhavan | Director |
Jun 20 '25 |
Sale |
14.45 |
2,112 |
30,518 |
37,697 |
| Meek David D. | Director |
Jun 20 '25 |
Sale |
14.45 |
2,112 |
30,518 |
34,190 |
| Potts Jeannette | Chief Legal Officer |
Jun 16 '25 |
Sale |
15.14 |
4,670 |
70,704 |
115,073 |
| Kapusta Matthew C | CEO, Managing Director |
Mar 04 '25 |
Sale |
10.29 |
28,341 |
291,629 |
651,454 |
| Abi-Saab Walid | Chief Medical Officer |
Mar 04 '25 |
Sale |
10.29 |
1,350 |
13,891 |
151,903 |
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):